Report Details

How to find trends and revenue predictions for epigenetics

What does the future hold for epigenetic applications? Visiongain's new report gives you revenue predictions to 2023 for those therapies, technologies and diagnostic products. There you find sales data, R&D trends, opportunities and commercial prospects.

That analysis lets you assess forecasted sales at overall world market, submarket, product, regional and national level. You discover the potential of the industry and market for epigenetics, seeing where that field is heading.

Forecasts and other analyses to help you find the best opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 70 tables, 47 charts and two research interviews.

Our work lets you investigate the most lucrative areas in that industry and market. Those technologies hold great promise.

The following sections show what you see in our updated report.

You discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see individual forecasts for three epigenetic submarkets to 2023:
• Therapies
• Technologies
• Diagnostics.

You can gain advantages by understanding trends, opportunities and challenges for epigenetics. Our investigation shows what will stimulate and restrain business.

Also, how will existing and expected products - Vidaza, Dacogen, Zolinza, Istodax, Belinostat and Faridak - perform at world level to 2023? You see forecasts and discussions for those drugs.

Our work also breaks the overall world forecast into leading geographical markets.

What prospects for leading regions and countries?

Developments worldwide will influence the market from 2013. There are many opportunities for healthcare companies large and small.

You discover individual revenue forecasts to 2023 for eight national markets and two regional blocks. Find relevant overall sales:
• US
• Canada
• Japan
• Germany, France, UK, Italy and Spain (EU5 countries)
• Europe
• Brazil, Russia, India and China (BRIC nations, grouped analysis).

You find potential. High sales growth will occur in established pharma markets and in developing countries, our analyses show. In particular, drug launches will change the commercial landscape to 2023.

Research and development - see trends and possibilities

What's happening in epigenetic R&D? You see trends and outlooks there:
• HDAC inhibitors
• DNMT inhibitors
• Treatments targeting other enzymes
• MiRNA therapy
• Diagnostics pipeline.

Our study also discusses these technologies, among others:
• New drug targets
• Biomarkers
• Bioinformatics
• Next generation sequencing.

Discover progress. You assess innovations affecting the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects the application of epigenetics?

Our report discusses issues and events affecting that science, industry and market from 2013 onwards:
• Cancer research and treatment
• DNA hypomethylation in autoimmune diseases
• Neurodegenerative diseases
• Neurological disorders
• Understanding of epigenetic markers and mechanisms.

Also, you find coverage of these aspects of the field:
• Genomics, proteomics and metabolomics
• Translational research
• Licensing, outsourcing and academic collaborations
• Developments with stem cells
• Orphan indications and patient subpopulations
• Companion diagnostics and stratified medicine.

See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on companies, competition and business outlooks.

Leading companies and market value

Overall world revenue for epigenetic applications will reach $2,518m in 2013, our report forecasts. The R&D pipeline is diverse and promising. That industry holds great potential for further investment, development and growth.

In our study you find discussions of these organisations and many others:
• Celgene
• Eisai
• Merck & Co.
• Roche
• Astex Pharmaceuticals
• Exact Sciences
• Orion Genomics.

This decade, many opportunities will arise. Our work shows you the technological and commercial possibilities.

Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you

To sum up, our investigation gives you the following knowledge on the topic:
• Forecasted revenues to 2023 for the overall world market and 3 submarkets - you discover prospects for the industry's future
• Predicted revenues of 6 products to 2023 - you find prospects for drugs, both existing brands and those awaiting launch
• Market forecasting to 2023 for US, Canada, Japan, Germany, France, UK, Spain, Italy, BRIC nations and Europe - you see national and regional outlooks
• Assessments of companies - you find activities, products, strategies and outlooks
• Review of R&D by technology and disease - you hear about progress in established and emerging research areas
• Opinions on the sector - you read our interviews with leaders in that industry
• Competition and opportunities influencing sales - you see what affects the future
• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.

You gain information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.

With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.

Ordering now lets you discover commercial prospects to 2023 for epigenetics

Visiongain's study is for everyone needing forward-looking analysis of pharmaceutical and diagnostic biotechnology. You find data, trends and predictions. Please ask for our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table Of Contents

Table of Contents
1. Executive Summary
1.1 Epigenetic Therapies and Technologies: World Market Review
1.2 Report Contents
1.3 Research and Analysis Methods

2. An Introduction to Epigenetics
2.1 How is Epigenetics Defined?
2.1.1 Epigenetic Mechanisms
2.1.2 A Brief History of Epigenetic Research
2.2 The Links between Epigenetics and Disease
2.2.1 The Role of Lifestyle in Epigenetics
2.2.2 Epigenetics and Cancer
2.2.3 Epigenetics in Inherited Disorders
2.2.4 Epigenetics in Neurological Diseases
2.3 Epigenetics for Disease Diagnosis
2.3.1 Diagnosing for Breast Cancer
2.3.2 Colorectal Cancer: The Importance of Early Diagnosis
2.3.3 Diagnostics for Lung Cancer: Difficulty in Accessing Samples
2.3.4 Diagnostics for Prostate Cancer
2.4 The Use of Epigenetics in Treating Disease
2.4.1 DNA Methyltransferase (DNMT) Inhibitors
2.4.1.1 Myelodysplastic Syndromes (MDS)
2.4.2 Histone Deacetylase (HDAC) Inhibitors
2.4.2.1 Cutaneous T Cell Lymphoma (CTCL)
2.4.2.2 Peripheral T Cell Lymphoma (PTCL)
2.5 Drug Discovery and Development Tools Using Epigenetics
2.5.1 Bisulphite Screening for DNA Methylation
2.5.2 Chromatin Immunoprecipitation (ChIP) for Histone Modification

3. The Epigenetic Therapies and Technologies Market 2013-2023
3.1 The Epigenetic Therapies and Technologies Market 2011-2012
3.1.1 Leading Sectors of the Market 2011-2012
3.2 The Epigenetic Therapies and Technologies Market 2013-2023
3.2.1 The Epigenetic Therapies and Technologies Market: Overall Revenue Forecast 2013-2023
3.2.2 What Will Drive Revenue Growth for Epigenetic Therapies and Technologies?
3.2.3 Rising Importance for Diagnostics Revenue 2013-2023
3.3 Epigenetic Therapies Submarket 2013-2023
3.3.1 Epigenetic Therapies Submarket: Revenue Forecast 2013-2023
3.3.2 Factors Influencing Epigenetic Therapy Uptake and Revenues 2013-2023
3.4 Epigenetic Technologies Submarket 2013-2023
3.4.1 Epigenetic Technologies Submarket: Revenue Forecast 2013-2023
3.4.2 Epigenetic Technologies Submarket: Drivers and Restraints 2013-2023
3.5 Epigenetic Diagnostics Submarket 2013-2023
3.5.1 Epigenetic Diagnostics Submarket: Revenue Forecast 2013-2023
3.5.2 New Product Launches to Drive Growth 2013-2023

4. Leading National Epigenetic Therapy and Technology Markets 2013-2023
4.1 Leading National Markets for Epigenetic Therapies and Technologies 2011-2012
4.2 Leading National Markets: Revenue Forecasts 2013-2023
4.2.1 The Continued Dominance of Western Markets 2013-2023
4.3 The North American Market 2013-2023
4.3.1 The US: The World's Largest Market for Epigenetic Therapies and Technologies 2013-2023
4.3.2 Canada: Revenues 2013-2023
4.4 The European Market 2011-2012
4.4.1 Leading National Markets in Europe: Revenue Forecasts 2013-2023
4.4.2 Germany: Revenues 2013-2023
4.4.3 The UK: A Leading Market for Epigenetics Research
4.5 Japan: Recent Entry of the Epigenetic Therapies Market
4.6 Epigenetics in Emerging Markets
4.6.1 BRIC Nations: Rising Importance for Epigenetic Therapies and Technologies 2013-2023

5. Epigenetic Therapies Market 2013-2023
5.1 Changes to the Epigenetic Therapies Market 2013-2023
5.2 Vidaza: The First Epigenetic Therapy Approved
5.2.1 Vidaza: Strong Revenue Growth 2004-2011
5.2.2 Development as a Combination Therapy to Drive Growth
5.2.3 Vidaza: Revenue Forecast 2013-2023
5.3 Dacogen
5.3.1 Revenue Performance 2004-2011
5.3.2 Approval in the EU in 2012 to Drive Revenue Growth
5.3.3 Dacogen: Revenue Forecast 2013-2023
5.4 Zolinza
5.4.1 Zolinza as a Potential Treatment for Multiple Myeloma
5.4.2 Zolinza: Revenue Forecast 2013-2023
5.5 Istodax
5.5.1 US PTCL Approval
5.5.2 Istodax: Revenue Forecast 2013-2023
5.6 Rich Pipeline for HDAC Inhibitors in 2012
5.6.1 Belinostat: A Selective HDAC Inhibitor for PTCL
5.6.2 Faridak for Velcade-Refractory Multiple Myeloma
5.6.3 Entinostat (Syndax Pharmaceuticals)
5.6.4 Resminostat (4SC)
5.6.5 Pracinostat: The First Epigenetic Therapy Developed in Singapore
5.6.6 Mocetinostat Has Been Tested in More Than 12 Clinical Trials
5.6.7 Quisinostat (Centocor Research and Development)
5.6.8 Rocilinostat (Acetylon Pharmaceuticals)
5.6.9 CHR-3996 (Chroma Therapeutics)
5.6.10 Givinostat for Cancer, Autoimmune and Neurodegenerative Diseases
5.6.11 SHP-141 (Shape Pharmaceuticals)
5.6.12 EVP-0334 (EnVivo Pharmaceuticals/MethylGene)
5.6.13 4SC-202 (4SC)
5.6.14 Tefinostat (Chroma Therapeutics)
5.6.15 CXD101 (Celleron Therapeutics)
5.6.16 Repligen: Epigenetic Therapies for Orphan Neurodegenerative Indications
5.6.17 Abexinostat (Pharmacyclics/Servier)
5.7 DNMT Inhibitor Pipeline 2012
5.7.1 SGI-110: A Second Generation DNMT Inhibitor
5.8 Pipeline Treatments Targeting Other Epigenetic Enzymes 2012
5.8.1 EPZ-5676: The First Clinical-Stage HMT Inhibitor
5.8.2 Oryzon Genomics: Targeting LSD1
5.8.3 Salarius Pharmaceuticals
5.8.4 Resverlogix Advancing BET Protein Inhibitors
5.9 MiRNA Therapy Pipeline 2012
5.9.1 Miravirsen (Santaris Pharma) is the Only Clinical-Stage miRNA Therapy
5.9.2 MRX34 (Mirna Therapeutics)
5.9.3 Regulus Therapeutics Is Collaborating with Big Pharma Players
5.10 Leading Epigenetic Therapy Manufacturers and Developers 2012
5.10.1 Celgene: Market Leader 2011-2012
5.10.2 Eisai
5.10.3 Merck and Co.
5.10.4 TopoTarget: Assessing Drug Commercialisation Strategies
5.10.5 Syndax Pharmaceuticals
5.10.6 4SC
5.10.7 Astex Pharmaceuticals is an Experienced Epigenetic Therapy Developer
5.10.8 Curis is Developing Multi-Targeted Therapies
5.10.9 CellCentric: Industry and Academic Collaboration for Drug Development
5.10.10 Constellation Pharmaceuticals
5.10.11 EpiTherapeutics
5.10.12 Epizyme Has Signed Valuable Big Pharma Collaboration Agreements
5.10.13 IkerChem: HDAC and DNMT Inhibitors in Cancer and CNS Disorders
5.10.14 Karus Therapeutics: HDAC Inhibitors for Inflammatory Diseases and Cancer

6. Epigenetic Diagnostics Market 2013-2023
6.1 Development of the Epigenetic Diagnostics Market 2013-2023
6.1.1 LDTs vs. IVDs: Two Diagnostic Development Strategies
6.2 Epigenetic Diagnostics Marketed 2012
6.2.1 Epi proColon 2.0 (Epigenomics)
6.2.1.1 ColoVantage (Quest Diagnostics)
6.2.1.2 Septin9 LDT (ARUP Laboratories)
6.2.2 ColoSure (LabCorp)
6.2.3 ConfirmMDx for Prostate Cancer (MDxHealth)
6.2.3.1 Gene Methylation in Prostate Cancer (LabCorp)
6.2.4 Epi proLung (Epigenomics)
6.2.5 MGMT Gene Methylation Assay (LabCorp)
6.2.6 Bladder Cancer Testing with CertNDx (Predictive Biosciences)
6.3 Epigenetic Diagnostics Pipeline 2012
6.3.1 The Future of Colorectal Cancer Testing
6.3.1.1 Cologuard: Using More Biomarkers to Improve Sensitivity
6.3.1.2 Orion Colorectal Cancer Risk Test (Orion Genomics)
6.3.1.3 PredictMDx (MDxHealth)
6.3.2 New Prognostic Tools in Development for Prostate Cancer
6.3.3 Lung Cancer
6.3.3.1 Lung Cancer Screening Test (Orion Genomics)
6.3.3.2 ConfirmMDx and InformMDx (MDxHealth)
6.3.4 Future Developments in Bladder Cancer Testing
6.3.4.1 Bladder Cancer Screening Test (Orion Genomics)
6.3.5 Other Cancer Tests in Development 2012
6.3.5.1 PredictMDx for Brain Cancer LDT (MDxHealth)
6.3.5.2 Pancreatic Cancer Prognostic Test (PrognosDx Health)
6.4 Leading Epigenetic Diagnostic Developers 2012
6.4.1 Epigenomics Markets Multiple Tests in the EU
6.4.1.1 Low Revenue in the EU 2010-2012
6.4.2 Exact Sciences and Colorectal Cancer Screening
6.4.3 MDxHealth: Targeting the US Diagnostics Market
6.4.3.1 Strong Revenue Growth 2009-2011
6.4.4 Orion Genomics Has Discovered More Than 100 Biomarkers
6.4.5 Predictive Biosciences
6.4.6 PrognosDx Health: Developing Epigenetic Prognostics

7. Epigenetic Technologies Market 2013-2023
7.1 Epigenetic Technology and Services Market 2013-2023
7.1.1 Outsourcing Epigenetic Discovery and Analysis
7.2 Next Generation Sequencing (NGS)
7.2.1 Lower Costs and Higher Speed for Expanded Research
7.2.2 Bottlenecks in Bioinformatics
7.2.3 Single Molecule Sequencing to Compete with NGS
7.3 Future Developments in Chromatin Immunoprecipitation
7.3.1 Considerations for ChIP-Seq
7.4 Future Developments in Bisulphite Screening
7.4.1 Techniques for Researching 5hmC Developed 2012
7.5 High Throughput Screening for Epigenetics
7.6 Leading Providers of Epigenetic Technologies 2012
7.6.1 Active Motif
7.6.2 Agilent Technologies: Measurement Tools for Epigenetic Research
7.6.3 Diagenode
7.6.4 DiscoveRx: Providing Tools to Research New Epigenetic Pathways
7.6.5 EMD Millipore
7.6.6 Epigentek Specialises in Epigenetic Technologies and Services
7.6.7 Epiontis: Epigenetics in Regenerative Medicine
7.6.8 Life Technologies: Cutting the Cost of NGS
7.6.9 Qiagen is Developing Epigenetic Technologies and Diagnostics
7.6.10 Roche

8. Research and Product Development Strategies in Epigenetics 2013-2023
8.1 The Epigenetic Therapies and Technologies Market by Disease 2013-2023
8.2 Present and Future Epigenetic Research in Cancer
8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer
8.2.2 Colorectal Cancer: Beyond Two Well-Established Biomarkers
8.2.3 Prognostic Markers in Lung Cancer
8.2.4 Prostate Cancer: Advances in Diagnostics, but Little Progress in Epigenetic Therapies
8.3 DNA Hypomethylation in Autoimmune Diseases
8.3.1 Lupus
8.3.2 Rheumatoid Arthritis as a Target for Drug and Diagnostic Development
8.3.2.1 Case Study: Ignyta, Pioneering Epigenetic Diagnostics in Rheumatoid Arthritis
8.3.3 Diabetes Incidence is Linked to Ageing and Diet
8.4 Neurodegenerative Diseases
8.4.1 Alzheimer's Disease: Alleviation of Symptoms Using HDAC Inhibitors
8.4.2 Huntington's Disease: Epigenetic Drugs Approaching Clinical Development
8.5 Neurological Disorders
8.5.1 Drug Resistance in Schizophrenia
8.5.2 Autism is Linked to Many Genetic and Epigenetic Mutations
8.6 New Epigenetic Drug Targets
8.6.1 BET Proteins Are a Target in Many Therapeutic Areas
8.6.2 Assessing and Understanding DNA Hydroxymethylation
8.6.3 Sirtuins as an Underexploited HDAC Inhibitor Class
8.6.4 Histone Methyltransferase
8.6.4.1 Lysine Methyltransferase
8.6.4.2 Case Study: Domainex Developing HMT Inhibitors
8.6.4.3 Protein Arginine Methyltransferases: Overcoming Insufficient Potency
8.6.5 Lysine Demethylases Show Promise as Targets for Cancer Therapies

9. Epigenetic Therapies and Technologies: Industry Trends 2013-2023
9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses 2011-2012
9.1.1 Understanding Epigenetic Markers and Mechanisms
9.1.2 Specificity of Current Epigenetic Therapies
9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats 2013-2023
9.2.1 The Importance of Translational Research
9.2.2 Developing Companion Diagnostics
9.2.3 Long Therapeutic and Diagnostic Pipelines
9.2.4 Combination Therapy with Epigenetic Drugs
9.2.5 Epigenetic Therapies to Overcome Drug Resistance
9.2.6 Drug Targets Beyond HDAC and DNMT Inhibition
9.3 Epigenetic Therapies and Technologies: STEP Analysis 2013-2023
9.4 Social Factors Influencing Product Development
9.4.1 Epigenetics and the Environment
9.4.2 Epigenetics, Ageing, and Disease
9.4.2.1 Rising Global Disease Incidence to Drive Epigenetics Market Growth
9.4.3 Targeting Orphan Indications and Patient Subpopulations
9.4.4 Epigenetics Can Lead to Personalised and Stratified Medicine
9.5 Technological Developments to Aid Epigenetic Research
9.5.1 Next-Generation Sequencing Improving Epigenetic Research
9.5.2 Using Epigenetics to Drive Forward Stem Cell Research
9.5.3 Complementary and Competing Technologies
9.5.3.1 Genomics
9.5.3.2 Proteomics
9.5.3.3 Metabolomics: A Comparatively New Discipline
9.6 Economic Factors
9.6.1 The Cost of Epigenetic Research
9.6.2 The Role of Big Pharma in the Epigenetics Market 2013-2023
9.6.2.1 Pfizer
9.6.2.2 Novartis: Performing Epigenetic Research in China
9.6.2.3 GSK Has Signed Many Deals in Epigenetics
9.6.3 Major Licensing Deals in Epigenetics
9.6.4 Epigenetic Business Models
9.7 Political Issues
9.7.1 Ethics in Epigenetic Research
9.7.2 Collaboration in Epigenetic Research
9.7.2.1 Structural Genomics Consortium
9.7.2.2 NIH Roadmap Epigenetics Project
9.7.2.3 International Human Epigenome Consortium
9.7.2.4 Blueprint: Contributing to Global Epigenome Libraries

10. Research Interviews
10.1 Dr James Rusche, SVP RandD, Repligen
10.1.1 The Advantage in Using HDAC Inhibitors
10.1.2 Combination Therapy Using HDAC Inhibitors
10.1.3 Challenges in Developing Epigenetic Drugs
10.1.3.1 Challenges Specific to Selective HDAC Inhibitors
10.1.4 Partnering for Epigenetic Drug Development
10.2 Dr Simon Kerry, CEO, Karus Therapeutics
10.2.1 Differences in Developing Selective and pan-HDAC Inhibitors
10.2.2 HDAC Inhibitors for Cancer and Other Diseases
10.2.3 Comparison of Kinase Inhibitor and HDAC Inhibitor Development
10.2.4 The Future of Epigenetic RandD

11. Conclusions from Our Study
11.1 Drugs Account for Most Epigenetic Revenues in 2012
11.2 Growth Expected in All Sectors of the Epigenetics Market 2013-2023
11.2.1 Developed Markets to Dominate 2013-2023
11.3 Many Opportunities Exist for Market Entry



List of Tables

Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Selected Enzymes Involved in Epigenetic Mechanisms
Table 2.2 Selected Treatments for MDS, 2012
Table 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011
Table 3.2 Epigenetic Therapies and Technologies Market: Overall Market and Revenue Forecasts by Sector, 2011-2023
Table 3.3 Epigenetic Therapies and Technologies Market: Drivers and Restraints, 2013-2023
Table 3.4 Epigenetic Therapies and Technologies Submarket Shares, 2011-2023
Table 3.5 Epigenetic Therapies Submarket by Drug, 2011
Table 3.6 Epigenetic Therapies Submarket: Overall Submarket and Revenue Forecasts by Drug, 2011-2023
Table 3.7 Epigenetic Therapies Submarket: Drivers and Restraints, 2013-2023
Table 3.8 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023
Table 3.9 Epigenetic Technologies Submarket: Drivers and Restraints, 2013-2023
Table 3.10 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023
Table 3.11 Epigenetic Diagnostics Submarket: Drivers and Restraints, 2013-2023
Table 4.1 Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.2 Epigenetic Therapies and Technologies in Developed Markets: Drivers and Restraints, 2013-2023
Table 4.3 Epigenetic Therapies and Technologies Market: Revenue Forecasts by Country, 2011-2023
Table 4.4 Epigenetic Therapies and Technologies in Emerging Markets: Drivers and Restraints, 2013-2023
Table 4.5 Epigenetic Therapies and Technologies: Market Shares by Country, 2011-2023
Table 4.6 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.7 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.8 European Epigenetic Therapies and Technologies Market by Country, 2011
Table 4.9 Selected Epigenetic Companies Headquartered in the EU, 2012
Table 4.10 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Leading Country, 2011-2023
Table 4.11 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.12 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.13 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 4.14 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Table 5.1 Epigenetic Therapies Submarket: Drug Revenue Shares, 2011-2023
Table 5.2 Vidaza: Revenue, 2004-2011
Table 5.3 Vidaza: Revenue by Region, H1 2011-2012
Table 5.4 Vidaza: Revenue Forecast, 2011-2023
Table 5.5 Vidaza: Drivers and Restraints, 2013-2023
Table 5.6 Dacogen: Revenue and Royalty Revenue, 2006-2011
Table 5.7 Dacogen: Phase III Clinical Trials, 2012
Table 5.8 Dacogen: Drivers and Restraints, 2013-2023
Table 5.9 Dacogen: Revenue Forecast, 2011-2023
Table 5.10 Zolinza: Drivers and Restraints, 2013-2023
Table 5.11 Zolinza: Revenue Forecast, 2011-2023
Table 5.12 Istodax: Revenue, 2010-2011
Table 5.13 CTCL and PTCL Prevalence by Region
Table 5.14 Istodax: Drivers and Restraints, 2013-2023
Table 5.15 Istodax: Revenue Forecast, 2011-2023
Table 5.16 Selected HDAC Inhibitors in Development, 2012
Table 5.17 NCI Sponsored Trials of Belinostat, 2012
Table 5.18 Belinostat: Revenue Forecast, 2014-2023
Table 5.19 Faridak: Revenue Forecast, 2014-2023
Table 5.20 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012
Table 5.21 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2012
Table 5.22 Selected MiRNA Therapy Pipeline, 2012
Table 5.23 CellCentric's Research Institution Affiliations, 2012
Table 5.24 IkerChem Epigenetic Pipeline, 2012
Table 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012
Table 6.2 Epigenomics: Revenue, 2010-2011
Table 6.3 MDxHealth: Pipeline, 2012
Table 6.4 MDxHealth: Revenue by Source, 2009-2011
Table 7.1 Fall in Average Cost of Sequencing the Human Genome, 2000-2012
Table 7.2 Selected Producers of Single-Molecule Sequencing Technologies, 2012
Table 7.3 Life Technologies: Revenue by Sector, 2010-2011
Table 8.1 Epigenetic Therapies and Technologies Market by Disease, 2011
Table 8.2 Prevalence of Cancers Targeted by Epigenetic Therapies, 2012
Table 9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses, 2011-2012
Table 9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats, 2013-2023
Table 9.3 Epigenetic Therapies and Technologies Market: STEP Analysis, 2013-2023
Table 9.4 Biomarker Development and Technologies Market Discipline, 2011
Table 9.5 Lucrative Licensing Deals for Epigenetic Therapies, 2011-2012
Table 9.6 Selected University Spin-Outs in the Epigenetics Industry, 1997-2011
Table 9.7 IHEC Member Organisations, 2012
Table 11.1 Epigenetic Therapies and Technologies Market by Sector, 2011-2023
Table 11.2 Epigenetic Therapies and Technologies Market by Region, 2011-2023



List of Figures

Figure 2.1 Stages of Cutaneous T Cell Lymphoma
Figure 2.2 Chromatin Immunoprecipitation (ChIP) Process
Figure 3.1 Epigenetic Therapies and Technologies Market by Sector, 2011
Figure 3.2 Epigenetic Therapies and Technologies Market: Overall Market Forecast, 2011-2023
Figure 3.3 Epigenetic Therapies and Technologies: Market Shares by Sector, 2017
Figure 3.4 Epigenetic Therapies and Technologies: Market Shares by Sector, 2023
Figure 3.5 Epigenetic Therapies Submarket by Drug, 2011
Figure 3.6 Epigenetic Therapies Submarket: Revenue Forecast 2011-2023
Figure 3.7 Epigenetic Technologies Submarket: Revenue Forecast, 2011-2023
Figure 3.8 Epigenetic Diagnostics Submarket: Revenue Forecast, 2011-2023
Figure 4.1 Epigenetic Therapies and Technologies Market by Country, 2011
Figure 4.2 Epigenetic Therapies and Technologies Market by Country, 2017
Figure 4.3 Epigenetic Therapies and Technologies Market by Country, 2023
Figure 4.4 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.5 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.6 European Epigenetic Therapies and Technologies Market by Country, 2011
Figure 4.7 European Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.8 French, Spanish and Italian Epigenetic Therapies and Technologies Markets: Revenue Forecasts, 2011-2023
Figure 4.9 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.10 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.11 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 4.12 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023
Figure 5.1 Epigenetic Therapies: Submarket Shares by Drug, 2017
Figure 5.2 Epigenetic Therapies: Submarket Shares by Drug, 2023
Figure 5.3 Vidaza: Revenue, 2004-2011
Figure 5.4 Vidaza: Revenue by Region, H1 2011-2012
Figure 5.5 Vidaza: Revenue Forecast, 2011-2023
Figure 5.6 Vidaza and Dacogen: Chemical Structures
Figure 5.7 Dacogen: Revenue and Royalty Revenue, 2006-2011
Figure 5.8 Dacogen: Revenue Forecast, 2011-2023
Figure 5.9 Zolinza: Revenue Forecast, 2011-2023
Figure 5.10 Istodax: Revenue, 2010-2011
Figure 5.11 Istodax: Revenue Forecast, 2011-2023
Figure 5.12 HDAC Inhibitor Expected Approvals, 2014-2019
Figure 5.13 Belinostat: Revenue Forecast, 2011-2023
Figure 5.14 Faridak: Revenue Forecast, 2011-2023
Figure 5.15 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer, 2012
Figure 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012
Figure 6.2 Epigenomics: Revenue, 2010-2011
Figure 6.3 MDxHealth: Revenue by Source, 2009-2011
Figure 7.1 Fall in Average Cost of Sequencing the Human Genome, 2000-2012
Figure 7.2 Life Technologies: Revenue by Sector, 2010-2011
Figure 8.1 Epigenetic Therapies and Technologies Market by Disease, 2011
Figure 8.2 Prevalence of Cancers Targeted by Epigenetic Therapies, 2012
Figure 9.1 Biomarker Development and Technologies by Market Discipline, 2011
Figure 11.1 Epigenetic Therapies and Technologies Market by Sector, 2011-2023
Figure 11.2 Epigenetic Therapies and Technologies Market by Region, 2011-2023


Companies Listed
4SC
4SC Discovery (part of 4SC)
Abbott Laboratories (AbbVie)
Accelerate Brain Cancer Cure
Accium BioSciences
Acetylon Pharmaceuticals
Active Motif
Agence Nationale de la Recherche (ANR) [France]
Agilent Technologies
Agios
Allos Therapeutics
American Cancer Society
Amgen
Applied Biosystems (part of Life Technologies)
ARUP Laboratories
Astellas Venture Management
Astex Pharmaceuticals
AstraZeneca
Aton Pharma (part of Merck and Co.)
Australian Alliance for Epigenetics
Bayer
BellBrook Labs
BGI (formerly Beijing Genomics Institute)
Biogen Idec
Boehringer Mannheim (part of Roche)
Boston Children's Hospital
Brabraham Institute [UK]
Bundesministerium für Bildung und Forschung (BMBF) [Germany]
Cambridge Institute for Medical Research
Canadian Epigenetics, Environment and Health Consortium
Canadian Institutes for Health Research (CIHR)
CanAm Bioresearch
Cancer Research Technology
Cancer Research UK
Celgene
CellCentric
Celleron Therapeutics
Cellzome (part of GSK)
Center for Genome Science [South Korea]
Centers for Medicare and Medicaid Services (CMS)
Centocor Research and Development (part of JandJ)
Centre de Regulació Genòmica [Spain]
Centre for Addiction and Mental Health [Canada]
Centre for Genomic Regulation [Barcelona]
Centre National de la Recherche Scientifique (CNRS)
Chiron (part of Novartis)
Chroma Therapeutics
Clavis Pharma
Companion Dx
Constellation Pharmaceuticals
Cornell University
Crelux
Curis
Dana-Farber Cancer Institute
Department of Biotechnology [India]
Diagenode
DiscoveRx
Domainex
Durviz
Eisai
Eli Lilly
Elixir Pharmaceuticals
EMA Committee for Medicinal Products for Human Use (CHMP)
EMD Millipore (part of Merck KGaA)
EnVivo Pharmaceuticals
EpigenDx
Epigenetics Dream Team
Epigenomics
Epigentek
Epiontis
EpiTherapeutics
Epizyme
European Commission
European Institute of Oncology (IEO)
European Medicines Agency (EMA)
European Patent Office
Exact Sciences
Flagship Biosciences
Food and Drug Administration (FDA) [US]
Friedreich's Ataxia Research Alliance (FARA)
Genentech (part of Roche)
Genomic Health
Genpathway (part of Active Motif)
Genzyme (part of Sanofi)
Gloucester Pharmaceuticals (part of Celgene)
Go FAR (Friedreich's Ataxia Research)
GSK
Harvard University
Health Canada
Helicos BioSciences
Hewlett-Packard
Ignyta
IkerChem
Imperial College London
Indian Institute of Science Education and Research
Institute of Cancer Research [UK]
Intelligent Bio-Systems (part of Qiagen)
International Human Epigenome Consortium (IHEC)
Italfarmaco
JandJ
Janssen-Cilag
Japan Science and Technology Agency (JST)
Japanese Society for Epigenetics
John Hopkins University
Karus Therapeutics
King's College London (KCL)
LabCorp
Leukemia and Lymphoma Society (LLS)
Life Technologies
Louis Pasteur University of Strasbourg
Lundbeckfond Ventures
M.D. Anderson Cancer Center
Macmillan Cancer Support
Massachusetts General Hospital
Mayo Clinic
McGill University
MDxHealth
MEI Pharma
Memorial Sloan-Kettering Cancer Center
Merck and Co.
Merck KGaA
Merck Serono Ventures
MethylGene
MGI Pharma (part of Eisai)
Michael J. Fox Foundation
Microgenics (part of Boehringer Mannheim)
Millennium Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW) [Japan]
MiReven
Mirna Therapeutics
Mitomics
Mount Sinai Medical Center
Multiple Myeloma Research Foundation
Muscular Dystrophy Association (MDA)
Myeloma UK
Myriad Genetics
National Ataxia Foundation (NAF)
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Human Genome Research Institute (NHGRI) [US]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute for Mental Health (NIMH) [US]
National Institutes of Health (NIH) [US]
NIH Roadmap Epigenomics Mapping Consortium [US]
Nippon Shinyaku
Novartis
Novo Nordisk
Novo Seeds
Nycomed
Odyssey Molecular
Onyx Pharmaceuticals
Orion Genomics
Oryzon Genomics
Otsuka Pharmaceutical
Pacific Biosciences
Pfizer
Pfizer Venture Investments
Pharmacyclics
Pharmion (part of Celgene)
PLUS Diagnostics
Predictive Biosciences
PrognosDx Health
Qiagen
Quest Diagnostics
Regulus Therapeutics
Repligen
Resverlogix
Roadmap Epigenomics Mapping Consortium [US]
Roche
Roche NimbleGen (part of Roche)
S*BIO (part of Chiron)
SABiosciences (part of Qiagen)
Salarius Pharmaceuticals
Sanofi
Santaris Pharma
Scottish Medicines Consortium (SMC)
Seed Capital
Servier
Shape Pharmaceuticals
Siena Biotech
Sigma-Aldrich
Spectrum Pharmaceuticals
Structural Genomics Consortium (SGC)
Swiss Life
Syndax Pharmaceuticals
Sysmex
Taiho Pharmaceutical
Takeda
Takeda Ventures
Technology Strategy Board (TSB) [UK]
Tensha Therapeutics
The Automation Partnership (now TAP Biosystems)
The Pharmaceutical Research and Manufacturers of America (PhRMA)
Thomas Jefferson University
TopoTarget
University College London (UCL)
University of Birmingham
University of California, Los Angeles (UCLA)
University of California, San Diego
University of Cambridge
University of Chicago
University of Copenhagen
University of Edinburgh
University of Liege
University of North Carolina
University of Nottingham
University of Oxford
University of Southampton
University of Southern California
University of the Basque Country
University of Toronto
University of Utah
University of Wuerzburg
Ventana Medical Systems (part of Roche)
Wellcome Trust
Wistar Institute
World Health Organization (WHO)
Yakult Honsha
ZoBio

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Photomedicine: Technologies and Global Markets

Photomedicine: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research study provides a comprehensive analysis of the market of photomedicine. It addresses the drivers and limiters of the market and offers an exhaustive analysis of both drugs and medical ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

  • $ 4 795
  • Industry report
  • September 2014
  • by Transparency Market Research

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream ...


10 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.